NCT01070823 - JC-Virus (JCV) Antibody Program | Biotech Hunter

Enrollment

1,096

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Multiple Sclerosis

Interventions

DRUG

Tysabri® (natalizumab)

Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program

Trial Locations (11)

Research Site, Brighton

Research Site, Raleigh

Research Site, Atlanta

Research Site, Cullman

Research Site, Farmington Hills

Research Site, Milwaukee

Research Site, Barrington

Research Site, Round Rock

Research Site, Aurora

Research Site, Portland

Research Site, Salt Lake City